CELL LINES
Contributor Information
- Name Medical-Industrial Translational Research Center
- Institute Fukushima Medical University
Tool Details
- Tool name: MCF10A-IDH1m-2 cell line
- Alternate names: 06M06003
- Clone: IDH1_type-02
- Tool type: Cell Lines
- Tool sub-type: Continuous
- Parental cell line: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
- Organism: Human
- Tissue: Mammarygland epithelium
- Cancer type: Non-tumorigenic
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Mutant
- Model description: Type: Type-02; Type mutation: R132C; CDS mutation: c.394C>T; AA mutation: p.R132C; COSMIC Mutation ID: COSM28747
- Application: Functional analysis of mutated genes, Drug screening
- Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, IDH1/2 (isocitrate dehydrogenase 1/2). IDH1/2 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The impact of IDH mutations on AML prognosis remains controversial, although a generally inferior outcome is seen with IDH1 mutations and a relatively favorable prognosismay be seen with IDH2 mutations, particularly R172K IDH2 mutations. In glioblastoma patients with IDH1/2 mutations have been associated with improved prognosis.
- Research area: Cancer; Cell biology
- For Research Use Only
Target Details
- Target: Isocitrate dehydrogenase (NADP(+)) 1, cytosolic [IDH1]
- Target background: Gene ID: 3417; References: DNA (mRNA): NM_005896.3; Protein: NP_005887.2
Application Details
- Application: Functional analysis of mutated genes, Drug screening
Handling
- Format: Frozen
- Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Â?g/ml insulin (human, recombinant), 5 Â?M forskolin, 0.5 Â?g/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Â?g/ml streptomycin
- Temperature: 37?C
- Atmosphere: Humidified incubator with 5%Â CO2
- Storage medium: CELLBANKER 2 (Zenogen pharma)
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry ice
- Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests
- Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
- Cultured in antibiotics?: 100 U/ml Penicillin, and 100 Â?g/ml Streptomycin
- Mycoplasma free: Yes
- Biosafety level: 1
Documentation
.svg)
.svg)
